Mylan's (MYL) Acqusition of Certain Abbott (ABT) Assets is Credit-Positive Development - Moody's

Moody's Investors Service commented that Mylan's (Nadaq: MYL) acquisition of a portion of the international established products business from Abbott Laboratories (NYSE: ABT) is credit positive because it will enhance Mylan's scale and diversity while reducing leverage and improving cash flows. However, we expect that Mylan will continue to actively pursue acquisitions which will likely be funded -- at least partly -- with debt. There is no change to Mylan's Baa3 rating or stable outlook. Please go to www.moodys.com for our full Issuer Comment.

The principal methodology used in this rating was Global Pharmaceutical Industry published in December 2012. Please see the Credit Policy page on www.moodys.com for a copy of this methodology.

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• PCF INSURANCE SERVICES SECURES $400 MILLION IN INCREMENTAL FINANCING AS PART OF NEW DELAYED DRAW TERM LOAN
• Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans